National Institute for Health Research, Nottingham Digestive Diseases Biomedical Research Centre, Nottingham University Hospitals NHS Trust, University of Nottingham, Nottingham, UK.
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Neurogastroenterol Motil. 2018 May;30(5):e13352. doi: 10.1111/nmo.13352.
While the pharmacological armamentarium for chronic constipation has expanded over the past few years, a substantial proportion of constipated patients do not respond to these medications. This review summarizes the pharmacological and behavioral options for managing constipation and details the management of refractory constipation. Refractory constipation is defined as an inadequate improvement in constipation symptoms evaluated with an objective scale despite adequate therapy (ie, pharmacological and/or behavioral) that is based on the underlying pathophysiology of constipation. Minimally invasive (ie, rectal irrigation and percutaneous endoscopic colostomy) and surgical therapies are used to manage refractory constipation. This review appraises these options, and in particular, percutaneous endoscopic colostomy, which as detailed by an article in this issue, is a less invasive option for managing refractory constipation than surgery. While these options benefit some patients, the evidence of the risk: benefit profile for these therapies is limited.
虽然近年来治疗慢性便秘的药物种类有所增加,但仍有相当一部分便秘患者对这些药物没有反应。本文综述了治疗便秘的药物和行为学选择,并详细介绍了难治性便秘的治疗方法。难治性便秘定义为尽管根据便秘的潜在病理生理学进行了适当的治疗(即药物和/或行为治疗),但用客观量表评估的便秘症状仍无明显改善。微创(即直肠灌洗和经皮内镜结肠造口术)和手术治疗用于治疗难治性便秘。本文对这些治疗选择进行了评估,尤其是经皮内镜结肠造口术,正如本期杂志中的一篇文章所述,与手术相比,该方法是一种治疗难治性便秘的侵袭性较小的选择。虽然这些治疗方法对某些患者有效,但这些治疗方法的风险-获益特征的证据有限。